Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review

Rituximab is a chimeric mouse-human antibody that targets the CD20 antigen, which is found in both normal and neoplastic B cells. In recent years, it has been increasingly used to treat cutaneous B-cell lymphoma and is now considered an alternative to classic treatment (radiotherapy and surgery) of...

Full description

Saved in:
Bibliographic Details
Published inActas dermo-sifiliográficas (English ed.) Vol. 105; no. 5; pp. 438 - 445
Main Authors Fernández-Guarino, M, Ortiz-Romero, P L, Fernández-Misa, R, Montalbán, C
Format Journal Article
LanguageEnglish
Spanish
Published 01.06.2014
Online AccessGet full text

Cover

More Information
Summary:Rituximab is a chimeric mouse-human antibody that targets the CD20 antigen, which is found in both normal and neoplastic B cells. In recent years, it has been increasingly used to treat cutaneous B-cell lymphoma and is now considered an alternative to classic treatment (radiotherapy and surgery) of 2 types of indolent lymphoma, namely, primary cutaneous follicle center lymphoma and primary cutaneous marginal zone B-cell lymphoma. Rituximab is also administered as an alternative to polychemotherapy in the treatment of primary cutaneous large B-cell lymphoma, leg type. Its use as an alternative drug led to it being administered intralesionally, with beneficial effects. In the present article, we review the literature published on the use of rituximab to treat primary cutaneous B-cell lymphoma.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1578-2190
DOI:10.1016/j.ad.2012.10.021